• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Sodium-glucose cotransporter-2 inhibitors may decrease incidence of recurrent gout flares

bySoroush NedaieandAlex Chan
October 11, 2023
in Chronic Disease, Endocrinology, Rheumatology
Reading Time: 3 mins read
Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout
Share on FacebookShare on TwitterShare on LinkedIn

1. Over a one-year period, the incidence of recurrent gout flares in patients with gout and diabetes was significantly lower in those who initiated sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment compared to other antidiabetic treatments.

2. Patients who initiated an SGLT2i experienced a lower risk of all-cause mortality relative to the comparison cohort.  

Evidence Rating Level: 2 (Good)

Study Rundown: Gout, the most common inflammatory arthritis, has exhibited rising prevalence and incidence globally. Despite available effective treatments, recurrent gout flares persist, causing significant pain and morbidity. Gout’s association with cardiovascular-metabolic conditions adds to its comorbidity burden, and studies highlight its increased risk of kidney and cardiovascular-related mortality. Current guidelines advocate long-term urate-lowering therapy (ULT) to prevent flares, but previous studies indicate inadequate ULT dosing and low ULT adherence. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), used to treat type 2 diabetes, show promise in reducing cardiovascular events and all-cause mortality, lowering serum urate levels, and reducing the risk of incident gout, yet their effects on recurrent gout flares and mortality in gout patients remain unstudied. Data from the IQVIA Medical Research Database (IMRD) in the UK was used to compare the risk of recurrent gout flares and all-cause mortality between patients initiating SGLT2i treatment and those initiating other antidiabetic medications in patients with gout and type 2 diabetes. The overall incidence of recurrent flares, the incidence of the first recurrent flare, and all-cause mortality were found to be significantly lower in the SGLT2i cohort than in the comparison cohort.

Click to read the study in JAMA Network Open

In-Depth [retrospective cohort]: Despite effective available treatments like ULT, many patients with gout continue to experience recurrent gout flares. Gout is also associated with an increased mortality risk from kidney and cardiovascular disease. SGLT2i has been shown to mitigate all-cause mortality risk, decrease urate levels, and reduce the risk of incident gout. This study aimed to determine the association between SGLT2i and recurrent gout flares along with all-cause mortality in patients with gout. From the IMRD, 5931 eligible patients with gout and diabetes were analyzed to compare the risk of recurrent gout flares and all-cause mortality in patients initiating SGLT2i and those initiating other antidiabetic medications. Of these patients, 1548 (mean [SD] age, 61.8 [10.6] years; 16.0% women) had initiated SGLT2i treatment, while 4384 patients (mean [SD] age, 67.5 [11.6] years; 24.6% women) had initiated treatment with the active comparators of glucagonlike peptide-1 receptor agonists (GLP-1 RA) or dipeptidyl peptidase-4 inhibitors (DPP-4i). Compared to the comparison cohort, patients in the SGLT2i cohort exhibited a decreased incidence of recurrent flares with a rate difference (RD) of −20.4 (95% CI, −39.6 to −1.2) per 1000 person-years and risk reduction (RR) of 0.79 (95% CI, 0.65-0.97). These associations were consistent across different subgroups. In addition, SGLTi initiation was associated with a 19% lower weighted incidence rate of the first recurrent flare and a weighted hazard ratio (HR) 0.81 (95% CI, 0.65-0.98). Finally, all-cause mortality was found to be 29% lower in the SGLT2i cohort than in the comparison cohort with a HR of 0.71 [95% CI, 0.52-0.97]. This lower risk of all-cause mortality was mainly observed when comparing initiators of DPP-4i (HR, 0.63 [95% CI, 0.48-0.84]) but not GLP-1 RA (HR, 1.12 [95% CI, 0.89-1.52]). Overall, these findings suggest in patients with gout and type 2 diabetes treatment with SGLT2i is associated with a lower risk of recurrent gout flares and lower all-cause mortality. 

RELATED REPORTS

In late-breaking phase 3 results, pozdeutinurad lowered serum urate through 12 months in patients with uncontrolled gout

The addition of leflunomide (Arava) to prednisone (Deltasone) may not improve rate of remission in Takayasu arteritis

 Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: allopurinolchronic diseasegoutrheumatologySGLT2i
Previous Post

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

Next Post

Ferric carboxymaltose does not improve heart failure with iron deficiency

RelatedReports

A liver illustration accompanied by a vial representing hepatitis C treatment and RNA, highlighting research in hepatology.
2MM Trial Briefs

In late-breaking phase 3 results, pozdeutinurad lowered serum urate through 12 months in patients with uncontrolled gout

October 30, 2026
Lower target oxygen saturation in extremely preterm infants appears safe
Chronic Disease

The addition of leflunomide (Arava) to prednisone (Deltasone) may not improve rate of remission in Takayasu arteritis

July 10, 2026
Obstetric scoring systems overestimate cases of severe sepsis
All Specialties

2 Minute Medicine Rewind July 6, 2026

July 7, 2026
Psoriatic arthritis collage: an engraved joint glowing teal between two bone ends, folded knit gloves and a jar of cream
Chronic Disease

Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis

June 5, 2026
Next Post

Ferric carboxymaltose does not improve heart failure with iron deficiency

#VisualAbstract: Prophylactic antibiotics prevent urinary tract infections in infants with vesicoureteral reflux

#VisualAbstract: Prophylactic antibiotics prevent urinary tract infections in infants with vesicoureteral reflux

Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder
  • In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity
  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.